Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

8.3K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.3K
Tumor Immunotherapy01:27

Tumor Immunotherapy

1.3K
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
1.3K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Construction of Coumarin-Conjugated Macromolecular Probe for Photoactivatable Bioimaging.

Luminescence : the journal of biological and chemical luminescence·2026
Same author

Backbone N-heteroatom substitution as a strategy to enhance peptide proteolytic stability.

RSC chemical biology·2026
Same author

Solid-phase synthesis and biological evaluation of des-hydroxy pseudouridimycin analogs.

ACS medicinal chemistry letters·2026
Same author

Fluctuating β-Sheet Secondary Structure in DS119 Explains the Small Effects of Backbone N-Amination on Thermal Stability.

Journal of peptide science : an official publication of the European Peptide Society·2026
Same author

Chemical Ligation of Backbone N-hydroxylated Peptides.

Chemistry (Weinheim an der Bergstrasse, Germany)·2026
Same author

From the Clinic, to the Clinic: Improving the Fluorescent Imaging Quality of ICG via Amphiphilic NIR-IIa AIE Probe.

Biosensors·2026

Related Experiment Video

Updated: Dec 6, 2025

Analyzing Tumor and Tissue Distribution of Target Antigen Specific Therapeutic Antibody
07:36

Analyzing Tumor and Tissue Distribution of Target Antigen Specific Therapeutic Antibody

Published on: May 16, 2020

5.7K

Development of Tumor-Targeting IRE-1 Inhibitors for B-cell Cancer Therapy.

Andong Shao1, Qin Xu1, Walker T Spalek1

  • 1The Wistar Institute, Philadelphia, Pennsylvania.

Molecular Cancer Therapeutics
|October 14, 2020
PubMed
Summary

Novel inhibitors targeting XBP-1 splicing show promise for B-cell cancers. Tricyclic chromenone compounds B-I09 and D-F07 effectively suppress XBP-1s expression in multiple myeloma, enhancing therapeutic strategies.

More Related Videos

Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology
07:04

Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology

Published on: May 2, 2025

904
Ex vivo Expansion of Tumor-reactive T Cells by Means of Bryostatin 1/Ionomycin and the Common Gamma Chain Cytokines Formulation
07:20

Ex vivo Expansion of Tumor-reactive T Cells by Means of Bryostatin 1/Ionomycin and the Common Gamma Chain Cytokines Formulation

Published on: January 14, 2011

15.1K

Related Experiment Videos

Last Updated: Dec 6, 2025

Analyzing Tumor and Tissue Distribution of Target Antigen Specific Therapeutic Antibody
07:36

Analyzing Tumor and Tissue Distribution of Target Antigen Specific Therapeutic Antibody

Published on: May 16, 2020

5.7K
Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology
07:04

Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology

Published on: May 2, 2025

904
Ex vivo Expansion of Tumor-reactive T Cells by Means of Bryostatin 1/Ionomycin and the Common Gamma Chain Cytokines Formulation
07:20

Ex vivo Expansion of Tumor-reactive T Cells by Means of Bryostatin 1/Ionomycin and the Common Gamma Chain Cytokines Formulation

Published on: January 14, 2011

15.1K

Area of Science:

  • Molecular Biology
  • Cancer Therapeutics
  • Biochemistry

Background:

  • The X-box binding protein 1 (XBP-1) pathway, specifically its spliced form (XBP-1s), is crucial for the survival and growth of B-cell malignancies like multiple myeloma (MM).
  • Existing inhibitors of XBP-1s expression exhibit variable efficacy and cytotoxicity against cancer cells, necessitating the development of more effective therapeutic agents.

Purpose of the Study:

  • To systematically compare the efficacy of various XBP-1s inhibitors in vitro and in preclinical models.
  • To identify potent inhibitors of IRE-1 kinase/RNase activity for improved B-cell cancer treatment strategies.

Main Methods:

  • In vitro assessment of IRE-1 RNase inhibition by different compounds.
  • Evaluation of XBP-1s expression suppression in mouse and human multiple myeloma cell lines.
  • Combination studies with PI3K/AKT pathway inhibitors and development of stimuli-responsive prodrugs.

Main Results:

  • Tricyclic chromenone-based inhibitors, B-I09 and D-F07, demonstrated reliable and potent suppression of XBP-1s expression in MM cells.
  • The cytotoxicity of B-I09 and D-F07 was enhanced when combined with PI3K/AKT pathway inhibitors.
  • Development of stimuli-responsive prodrugs with improved tumor-targeting efficiency through chemical modifications.

Conclusions:

  • B-I09 and D-F07 are effective inhibitors of XBP-1s expression and show potential for treating multiple myeloma and other B-cell lymphomas.
  • Combination therapies and novel prodrug designs offer promising avenues for enhancing the efficacy and targeting of XBP-1s inhibitors in cancer treatment.